Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar Pain

Study Purpose

This is a Pilot Study that is an open label, prospective, non-controlled study in which the safety and feasibility of Wharton's Jelly (WJ) allograft will be evaluated in 100 participants suffering with low back pain.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 20 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

• Patient must.
  • - Be over age 20.
  • - Suffering from chronic lumbar pain.
  • - Body Mass Index (BMI) <50 Kilograms/m2.
  • - Pain score of 4 or more on the Numeric Pain Rating Scale (NPRS).
  • - Female participants must be abstinent, surgically sterilized or postmenopausal.
  • - Premenopausal females must be on contraceptive measures and do not anticipate pregnancy during the duration of the study.
  • - Be willing and capable of giving written informed consent to participate in English.
  • - Be willing and capable of complying with study-related requirements, procedures and visits.

Exclusion Criteria:

• Patient must not.
  • - Have taken any pain medication including nonsteroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to study injection date.
  • - Use anticoagulants have a substance abuse history, and fail to agree not to take any lumbar symptom modifying drugs during the course of the study without discussing and reporting the use to the site Clinical investigator and study team.
  • - Known allergy to penicillin, sulfa or amphotericin medications.
  • - Have had any lumbar injections (at all) of any drug in lumbar spine in the past 6 months.
  • - Have had surgery on the lumbar spine within the past 6 months.
  • - Had a traumatic injury to the lumbar spine with the past 3 months.
  • - Planned elective surgery during the course of the study.
  • - A history of organ or hematologic transplantation, rheumatoid arthritis, or other autoimmune disorders.
  • - Be on immunosuppressive medications.
  • - Have a diagnosis of carcinoma with the past 5 years.
  • - Have a lumbar infection or have used antibiotics for lumbar infection within the past 3 months.
  • - Have participated in any other clinical study or treatment (not just for the lumbar spine, but for any reason) with any investigational product within the past 30 days prior to inclusion of study.
  • - Female participants who are breast feeding or are pregnant or desire to become pregnant during the course of the study.
  • - Contraindications to radiographic or MRI imaging.
  • - Serious neurological, psychological or psychiatric disorders.
  • - Injury or disability claims under current litigation or pending or approved workers compensation claims.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT06361485
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

R3 Stem Cell
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

James Faber, BA
Principal Investigator Affiliation Institute of Cellular and Regenerative Medicine IRB
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Low Back Pain
Additional Details

This is a prospective, open label, non-controlled Pilot study in which the safety and feasibility of umbilical cord Wharton's Jelly (WJ) allograft will be evaluated in participants suffering with lumbar pain. The participants will receive a series of lumbar injections described in the protocol. As this is a Pilot study primarily designed to evaluate safety, no control will be used. The dosing will consist of 10cc WJ Allograft with 100 total participants. In addition to baseline outcome instruments along with imaging and laboratory studies, participants will be followed for one year for evaluation of safety, pain relief and functional improvements.

Arms & Interventions

Arms

Experimental: Lumbar Injection Arm

Lumbar Injections with 10cc's of Umbilical Cord Wharton's Jelly Allograft (BelloWJY)

Interventions

Biological: - Lumbar Injections with 10cc's of Wharton's Jelly Allograft

Low Back Injections with Minimal Manipulation Umbilical Cord Tissue

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

R3 Anti Aging Scottsdale, Scottsdale, Arizona

Status

Recruiting

Address

R3 Anti Aging Scottsdale

Scottsdale, Arizona, 85262

Site Contact

David Greene, MD, PhD, MBA

[email protected]

480-306-6256

R3 Anti Aging Beverly Hills, Beverly Hills, California

Status

Recruiting

Address

R3 Anti Aging Beverly Hills

Beverly Hills, California, 90210

Site Contact

Kathleen Francesca, BA

[email protected]

424-382-1074

Scheer Medical Wellness, New York, New York

Status

Recruiting

Address

Scheer Medical Wellness

New York, New York, 10036

Site Contact

Alexandre Scheer, MD

[email protected]

646-762-9499

Dr. Duc (Steve) Le, MD, Cleveland, Texas

Status

Recruiting

Address

Dr. Duc (Steve) Le, MD

Cleveland, Texas, 77327

Site Contact

Steve Le, MD

[email protected]

281-593-1500